IP Library Granted Patent US 7,211,402
Granted Patent B2
US 7,211,402 · App. 10/971,982 · Granted May 1, 2007

Transcription factor coactivator protein, p/CIP

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,211,402
App. No.
10/971,982
Granted
May 1, 2007
Kind
B2
Abstract

The present invention provides a substantially purified nucleic acid molecule encoding a p/CIP polypeptide, which regulates the activity of CBP/p300-dependent transcription factors. The invention also provides a substantially purified p-CIP polypeptide and active fragments thereof. In addition, the invention provides methods of identifying an effective agent that alters the association of a p/CIP polypeptide with a second protein. Further provided herein are methods of selectively inhibiting signal transduction pathways using an active fragment of a p/CIP polypeptide or a nucleic acid molecule encoding such an acive fragment.

Claims (12)

1. A substantially purified p/CIP polypeptide comprising the amino acid sequence shown in (SEQ ID NO.: 2).

2. A substantially purified active fragment of a murine p/CIP polypeptide, which fragment comprises a CBP interaction domain of a murine p/CIP polypeptide comprised of SEQ ID NO.: 2.

3. The substantially purified fragment of claim 2 comprising an amino acid sequence selected from the group consisting of about amino acids 758 to about 1115, about amino acids 947 to 1084, and about amino acids 163 to 610 of p/CIP SEQ ID NO.: 2.

4. A substantially purified fragment of a murine p/CIP polypeptide, which fragment comprises an amino acid sequence selected from the group consisting of about amino acids 591 to 803, and about amino acids 680 to 740 of p/CIP SEQ ID NO.: 2.

5. A substantially purified fragment of a murine p/CIP polypeptide, which fragment comprises a sequence selected from the group consisting of amino acid sequences 609–621, 670–684, 723–738, 1037–1049, and 1058–1068 of p/CIP SEQ ID NO.: 2.

6. A method of identifying an effective agent that alters the association of a p/CIP polypeptide of claim 1 with a second protein, comprising the steps of:

(a) contacting the p/CIP polypeptide and the second protein with an agent under conditions that allow the p/CIP polypeptide to associate with the second protein; and

(b) detecting an altered association of the p/CIP polypeptide and the second protein.

7. The method of claim 6 , wherein the second protein is selected from the group consisting of a CBP protein, a nuclear receptor and a CBP/p300-dependent transcription factor.

8. The method of claim 6 , wherein the altered association is detected by measuring the transcriptional activity of a reporter gene.

9. The method of claim 6 , wherein the contacting is in vitro.

10. The method of claim 6 , wherein the contacting is in a mammalian cell or a yeast cell.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 8, 2011
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027195/0815 →
Continuity (3)
Division 0944535300
Provisional Application 6004945200 · Jun 12, 1997
Related Publication 20050244889A1 · Nov 3, 2005